Founder, Infinitus, notes the the emerging themes at Access USA 2026, including regulatory shifts, the collapse of the traditional hub model, and the proliferation of fragmented AI point solutions. In ...

Are they destined to change the future of pharma? Nominate a colleague with impressive leadership and career intentions ...

Matt Turner, President of Patient Affordability, Paysign discusses the evolving financial threats to pharmaceutical ...

Launched in January, TrumpRx.gov is part of a series of most-favored-nation deals struck between the Trump administration and ...

Icotyde is the first targeted oral peptide IL‑23 receptor antagonist, designed to interrupt a core psoriasis inflammatory axis while avoiding injection-based administration typical of IL‑23 biologics.

In today's Pharmaceutical Executive Daily, Novartis agrees to acquire a pan-mutant-selective inhibitor from Synnovation Therapeutics in a deal worth up to $3 billion while Collegium moves to acquire ...

Nominate a colleague with impressive leadership and career intentions – even yourself! – for the Pharmaceutical Executive ...

Matthew Turner, President of Patient Affordability, Paysign, touches on how evolving payer tactics appear to be pushing ...

This episode of The Ron Lanton Report examines how the relationship between policy and market behavior has fundamentally shifted. Regulatory signals are now moving valuations and shaping strategic ...

War in the Middle East disrupts pharmaceutical supply chains in the Gulf region, forcing drugmakers to reroute shipments of ...

FDA authorization of semaglutide 7.2 mg once weekly was supported by two 72-week Phase III programs and reviewed under the Commissioner’s National Priority Voucher, shortening standard timelines. STEP ...

Excalipoint Therapeutics closed an oversubscribed $68.7 million seed financing, one of the largest early-stage rounds for a Chinese biotechnology company, to advance its pipeline of six T-cell engager ...